Outcome Predictors of Candida Prosthetic Joint Infections: A Systematic Review and Meta-analysis
- PMID: 40463834
- PMCID: PMC12130970
- DOI: 10.1093/ofid/ofaf281
Outcome Predictors of Candida Prosthetic Joint Infections: A Systematic Review and Meta-analysis
Abstract
Background: Candida prosthetic joint infections (CPJI) are serious complications, for which optimal surgical management and antifungal therapy remain unclear. This systematic review and meta-analysis aimed at defining the outcome predictors of CPJI.
Methods: A systematic literature review was performed in PubMed, Medline, Embase, and Web of Science until July 2024. Articles (cohorts, case-series or case reports) reporting individual data of adult patients with CPJI were included. Data about underlying conditions, characteristics of infection, and outcomes were collected. Outcome predictors were assessed in univariate analysis. Significant variables were included in a multivariate model using logistic regression with a binomial link function. Multicollinearity among the independent variables was assessed using the variance inflation factor.
Results: A total of 385 CPJI (including 204 hip and 152 knee infections) from 110 publications were included. Polymicrobial infections accounted for 33% cases. Candida albicans (47.2%) was the predominant species followed by Candida parapsilosis (28.6%). In multivariate analysis, independent predictors of failure were co-infection with Staphylococcus aureus (odds ratio, 0.4; 95% confidence interval, 0.18-0.92; P = .032) and debridement/retention of the prosthesis (0.25; 0.11-0.55; P < .001), whereas first-line therapy with amphotericin B was associated with success (3.18; 1.25-9.87; P = .014). No difference according to the type of prosthesis exchange procedure (1, 2, or 3 stages) was found. Use of local antifungal therapy (eg, antifungal drug-impregnated spacers) had no significant impact on outcome.
Conclusions: This study confirms the importance of complete hardware removal in CPJI. Most importantly, it provides evidence supporting the use of amphotericin B as initial antifungal therapy.
Keywords: arthroplasty; candidiasis; hip; knee; prosthesis.
© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Conflict of interest statement
Potential conflicts of interest. F.L. reports research funding from Gilead, MSD, Pfizer, and Novartis, honoraria for conferences from Gilead, MSD, Pfizer, Mundipharma, and Becton-Dickinson, and travel grants from MSD, Pfizer, and Gilead. All contracts were made with and fees paid to his institution (CHUV). B.G. reports a research funding from Tillotts Pharma. Contract was made with and fees paid to his institution (CHUV). All other authors report no potential conflicts.
References
-
- Marang-van de Mheen PJ, Bragan Turner E, Liew S, et al. Variation in prosthetic joint infection and treatment strategies during 4.5 years of follow-up after primary joint arthroplasty using administrative data of 41397 patients across Australian, European and United States hospitals. BMC Musculoskelet Disord 2017; 18:207. - PMC - PubMed
-
- Tabaja H, Abu Saleh A, Osmon DR. Periprosthetic joint infection: what's new? Infect Dis Clin North Am 2024; 38:731–56. - PubMed
-
- Gross CE, Della Valle CJ, Rex JC, Traven SA, Durante EC. Fungal periprosthetic joint infection: a review of demographics and management. J Arthroplasty 2021; 36:1758–64. - PubMed
LinkOut - more resources
Full Text Sources